Northland Securities reissued their buy rating on shares of Motif Bio PLC (LON:MTFB) in a report published on Monday. Northland Securities currently has a GBX 114 ($1.42) price objective on the stock.

Separately, Beaufort Securities downgraded shares of Motif Bio PLC to a hold rating in a report on Wednesday, August 17th.

Shares of Motif Bio PLC (LON:MTFB) traded up 0.1023% during mid-day trading on Monday, hitting GBX 24.2748. 2,519,540 shares of the company were exchanged. The firm’s market capitalization is GBX 26.36 million. Motif Bio PLC has a 12-month low of GBX 23.25 and a 12-month high of GBX 68.25. The company’s 50-day moving average price is GBX 43.01 and its 200-day moving average price is GBX 47.46.

About Motif Bio PLC

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).

Receive News & Stock Ratings for Motif Bio PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio PLC and related stocks with our FREE daily email newsletter.